Central Precocious Puberty: Update on Diagnosis and Treatment

Melinda Chen, Erica A. Eugster

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Central precocious puberty (CPP) is characterized by the same biochemical and physical features as normally timed puberty but occurs at an abnormally early age. Most cases of CPP are seen in girls, in whom it is usually idiopathic. In contrast, ~50 % of boys with CPP have an identifiable cause. The diagnosis of CPP relies on clinical, biochemical, and radiographic features. Untreated, CPP has the potential to result in early epiphyseal fusion and a significant compromise in adult height. Thus, the main goal of therapy is preservation of height potential. The gold-standard treatment for CPP is gonadotropin-releasing hormone (GnRH) analogs (GnRHa). Numerous preparations with a range of delivery systems and durations of action are commercially available. While the outcomes of patients treated for CPP have generally been favorable, more research about the psychological aspects, optimal monitoring, and long-term effects of all forms of GnRHa treatment is needed. Several potential therapeutic alternatives to GnRHa exist and await additional investigation.

Original languageEnglish (US)
Pages (from-to)273-281
Number of pages9
JournalPediatric Drugs
Volume17
Issue number4
DOIs
StatePublished - Aug 29 2015

Fingerprint

Gonadotropin-Releasing Hormone
Therapeutics
Puberty
Central Precocious Puberty
Gold
Psychology
Research

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Pharmacology (medical)

Cite this

Central Precocious Puberty : Update on Diagnosis and Treatment. / Chen, Melinda; Eugster, Erica A.

In: Pediatric Drugs, Vol. 17, No. 4, 29.08.2015, p. 273-281.

Research output: Contribution to journalArticle

@article{83c06c01069c424684c1863cd9bf551a,
title = "Central Precocious Puberty: Update on Diagnosis and Treatment",
abstract = "Central precocious puberty (CPP) is characterized by the same biochemical and physical features as normally timed puberty but occurs at an abnormally early age. Most cases of CPP are seen in girls, in whom it is usually idiopathic. In contrast, ~50 {\%} of boys with CPP have an identifiable cause. The diagnosis of CPP relies on clinical, biochemical, and radiographic features. Untreated, CPP has the potential to result in early epiphyseal fusion and a significant compromise in adult height. Thus, the main goal of therapy is preservation of height potential. The gold-standard treatment for CPP is gonadotropin-releasing hormone (GnRH) analogs (GnRHa). Numerous preparations with a range of delivery systems and durations of action are commercially available. While the outcomes of patients treated for CPP have generally been favorable, more research about the psychological aspects, optimal monitoring, and long-term effects of all forms of GnRHa treatment is needed. Several potential therapeutic alternatives to GnRHa exist and await additional investigation.",
author = "Melinda Chen and Eugster, {Erica A.}",
year = "2015",
month = "8",
day = "29",
doi = "10.1007/s40272-015-0130-8",
language = "English (US)",
volume = "17",
pages = "273--281",
journal = "Paediatric Drugs",
issn = "1174-5878",
publisher = "Adis International Ltd",
number = "4",

}

TY - JOUR

T1 - Central Precocious Puberty

T2 - Update on Diagnosis and Treatment

AU - Chen, Melinda

AU - Eugster, Erica A.

PY - 2015/8/29

Y1 - 2015/8/29

N2 - Central precocious puberty (CPP) is characterized by the same biochemical and physical features as normally timed puberty but occurs at an abnormally early age. Most cases of CPP are seen in girls, in whom it is usually idiopathic. In contrast, ~50 % of boys with CPP have an identifiable cause. The diagnosis of CPP relies on clinical, biochemical, and radiographic features. Untreated, CPP has the potential to result in early epiphyseal fusion and a significant compromise in adult height. Thus, the main goal of therapy is preservation of height potential. The gold-standard treatment for CPP is gonadotropin-releasing hormone (GnRH) analogs (GnRHa). Numerous preparations with a range of delivery systems and durations of action are commercially available. While the outcomes of patients treated for CPP have generally been favorable, more research about the psychological aspects, optimal monitoring, and long-term effects of all forms of GnRHa treatment is needed. Several potential therapeutic alternatives to GnRHa exist and await additional investigation.

AB - Central precocious puberty (CPP) is characterized by the same biochemical and physical features as normally timed puberty but occurs at an abnormally early age. Most cases of CPP are seen in girls, in whom it is usually idiopathic. In contrast, ~50 % of boys with CPP have an identifiable cause. The diagnosis of CPP relies on clinical, biochemical, and radiographic features. Untreated, CPP has the potential to result in early epiphyseal fusion and a significant compromise in adult height. Thus, the main goal of therapy is preservation of height potential. The gold-standard treatment for CPP is gonadotropin-releasing hormone (GnRH) analogs (GnRHa). Numerous preparations with a range of delivery systems and durations of action are commercially available. While the outcomes of patients treated for CPP have generally been favorable, more research about the psychological aspects, optimal monitoring, and long-term effects of all forms of GnRHa treatment is needed. Several potential therapeutic alternatives to GnRHa exist and await additional investigation.

UR - http://www.scopus.com/inward/record.url?scp=84938421545&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938421545&partnerID=8YFLogxK

U2 - 10.1007/s40272-015-0130-8

DO - 10.1007/s40272-015-0130-8

M3 - Article

C2 - 25911294

AN - SCOPUS:84938421545

VL - 17

SP - 273

EP - 281

JO - Paediatric Drugs

JF - Paediatric Drugs

SN - 1174-5878

IS - 4

ER -